Compare Recursion Pharmaceuticals Inc (RXRX) vs Yum China Holdings Inc (YUMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Yum China Holdings Inc — how do they compare? Recursion Pharmaceuticals Inc trades at $4.21 (market cap $2.14B), while Yum China Holdings Inc trades at $43.09 (market cap $14.11B). The key difference: Yum China Holdings Inc is far larger — about 6.6× Recursion Pharmaceuticals Inc's market cap, and Yum China Holdings Inc pays a 2.78% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Recursion Pharmaceuticals Inc for 22 Days and Yum China Holdings Inc for 77 Days on average.
| RXRX | YUMC | |
|---|---|---|
Market Cap | $2.14B | $14.11B |
Volume | 30,789,535 | 2,350,650 |
Sector | Health | Consumer Cyclical |
52-Week High | $6.79 | $57.95 |
52-Week Low | $2.84 | $39.98 |
Typical Hold Time | 22 Days | 77 Days |
Enterprise Value | $1.66B | $15.02B |
Dividend Yield | — | 2.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $4.05, down 5.15% today, with a bullish technical signal from moving averages. The company reported revenue of $74.26M in 2025 but a net loss of $644.76M, with negative profit margins. Recent news highlights strategic AI partnerships, including an extended data license with Tempus AI, aiming to fuel long-term growth despite current financial challenges.
The outlook remains speculative; the stock offers exposure to AI-driven drug discovery through a growing pipeline and partnerships, but high cash burn and lack of profitability pose significant risks. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for future catalysts tempered by near-term financial weakness.
YUMC trades at $40.65 with minimal daily movement (+0.07%). The stock shows strong fundamental performance with consistent earnings beats (Q4 2025-Q2 2026) and solid profitability metrics (ROE 17.5%, net margin 7.84%). Recent business developments include the acquisition of Pizza Hut brand ownership in mainland China and expansion of Pizza Hut Burger Bar to 300 locations. Technical indicators show bearish momentum with the stock trading near key support at $40.
YUMC presents a compelling value opportunity with reasonable valuation multiples (P/E 15.3, P/S 1.2) and strong analyst support (73.68% buy ratings). Upside potential exists from continued store expansion and brand innovation, though investors should monitor China's consumer spending trends and competitive pressures in the restaurant sector. The stock's current technical weakness may offer entry points for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Yum China Holdings Inc
With almost 10,600 units and USD 9.5 billion in systemwide sales in 2020, Yum China is the largest restaurant chain in China. It generates revenue through its own restaurants and franchise fees. Key concepts include KFC (7,166 units) and Pizza Hut (2,355), but the company's portfolio also includes other brands such as Little Sheep, East Dawning, Taco Bell, Huang Ji Huang, COFFii & Joy, and Lavazza (collectively representing about 985 units). Yum China is a trademark licensee of Yum Brands, paying 3% of total systemwide sales to the company it separated from in October 2016.
Read more on YUMC →
